Zürich, Switzerland, and Vienna, Austria – Sept. 24, 2025 – Cytosurge AG, a leader in single-cell manipulation technologies, and Lexogen, a pioneer in RNA sequencing solutions, today announced that their integrated Live-seq workflow is now available to academic researchers and industry partners worldwide. This breakthrough enables labs of any size to repeatedly sequence the same living cells, directly observing how gene expression shapes cellular behavior over time.​

Live-seq, validated in Nature (2022), represents a major advance over traditional destructive sequencing by preserving cell viability and enabling true longitudinal, time-resolved studies. Researchers can now not only take a snapshot of a cell state, but follow its state over time, pinpointing the molecular mechanisms behind drug responses, disease progression, and cell fate decisions.

Developed through a year of joint effort, the workflow integrates Cytosurge’s FluidFM® OMNIUM platform for minimally invasive cytoplasmic sampling, with Lexogen’s LUTHOR HD kit for ultra-sensitive RNA library preparation, plus comprehensive sequencing and data analysis support. By preserving cell viability, researchers can repeatedly sample RNA from the same living cells, unlocking true longitudinal, time-resolved transcriptomics and causally linked molecular and phenotypic data for applications in developmental biology, cancer research, and drug discovery.

“This launch marks a critical milestone for Live-seq adoption. By providing insights into the causal relationships driving cellular decision, we give scientists actionable therapeutic leads on ease never before possible,” said Dario Ossola, PhD, Chief Product Officer at Cytosurge. “Our partnership with Lexogen ensures this powerful technology is robust, scalable, and accessible to labs everywhere.”

"What excites me most is that we're democratizing access to live-cell sequencing,” added Filippo Passardi, PhD, Product Manager at Lexogen. “With the Live-seq workflow, including our LUTHOR HD kit, which can detect even single transcripts and produces complete gene expression profiles from less-than-a-cell samples, researchers now have a completely novel way to uncover the molecular ‘whys’ determining cell fate decisions.”

Researchers are invited to an upcoming webinar and encouraged to apply for Cytosurge’s Live-seq Access Program, which offers proof-of-principle studies for selected projects.

About Cytosurge 

Cytosurge is a biotechnology company transforming life sciences through its proprietary FluidFM® technology platform, with over 140 systems installed worldwide and 150+ peer-reviewed publications. FluidFM enables precise, nanoscale manipulation and analysis of living single cells. Live-seq leverages FluidFM for non-destructive, time-resolved RNA profiling, generating causally grounded data from individual cells to enable AI-driven predictive models and accelerate therapeutic discovery.
CellEDIT harnesses FluidFM for advanced, high-precision genome engineering through intra-nuclear CRISPR editing with minimal stress and off-target effects.
For more information, visit Cytosurge website, follow @cytosurge, watch live-cell demonstrations on YouTube, and explore real-world use cases on the Cytosurge blog.

About Lexogen 

Lexogen is a leading company in RNA sequencing, providing innovative solutions for transcriptome analysis and RNA research. Our products and services are designed to meet the evolving needs of the scientific community, delivering end-to-end solutions for high-quality, reliable results. For more information, visit Lexogen website and follow @lexogen.

 Download the shared application note.

Contacts

• Cytosurge AG, Erica Fiorini, PhD, Media Relations & Scientific Community Manager
  Phone +41 77 267 08 33, Email media@cytosurge.com
• Lexogen GmbH, Amra Dedic, Brand and Event Manager
  Phone +43 660 69 66 045, Email amra.dedic@lexogen.com